Impact of Oncotype DX Recurrence Score on the Patterns of Locoregional Recurrence in Breast Cancer (Korean Radiation Oncology Group 19-06) by 김용배 & 장지석
314
ABSTRACT
The current study evaluated the impact of the Oncotype DX recurrence score (RS) on the 
patterns of locoregional recurrence (LRR) in node-negative, hormone receptor-positive/
human epidermal growth factor receptor 2-negative breast cancer. Totally, 339 patients from 
4 institutions were enrolled and analyzed retrospectively. All patients underwent breast-
conserving surgery followed by whole-breast irradiation; only 2 patients received regional nodal 
irradiation (RNI). The RS was < 11 in 55 patients, 11–25 in 241, and > 25 in 43. Sixty-two patients 
received adjuvant chemotherapy. All patients except 4 received hormonal therapy. During a 
62-month median follow-up, local recurrence was observed in 1 patient; regional recurrence, 3; 
and distant metastasis, 7. All LRRs were observed among patients with a RS > 25, resulting in 
a 5-year LRR rate of 7.3% in this subgroup. Regional recurrences developed in patients did not 
receive RNI initially. Thus, RNI might be effective for patients with a high RS.
Keywords: Breast neoplasm; Local neoplasm recurrence; Radiotherapy
As two randomized trials showed the benefit of regional nodal irradiation for early breast 
cancer [1,2], comprehensive regional radiotherapy (RT) has been recommended for patients 
with node-positive breast cancer. In contrast, 15% of the study population was node-
negative in the Canadian randomized trial [1] and 44% in the European randomized trial 
[2]. In particular, in the latter study, the disease-free survival rate improved after regional 
RT, regardless of nodal involvement [2]. On the basis of these findings, the National 
Comprehensive Cancer Network guidelines recommend that regional RT should be 
considered even for node-negative patients with central/medial tumors or for patients with 
tumors > 2 cm with risk factors such as young age or extensive lymphovascular invasion [3].
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On evaluating the impact of breast RT after breast-conserving surgery (BCS) for node-
negative disease, the Early Breast Cancer Trialists' Collaborative Group observed that the 
reduction of first recurrence after breast RT was consistent in most subgroups classified by 
age, grade, tumor size, and hormonal receptor status [4]. More recently, however, genomic 
biomarkers are increasingly being investigated to select patients who will most benefit from 
breast RT [5,6]. Among the various genomic biomarkers, the Oncotype DX recurrence score 
(RS) is the most popular biomarker for patients with node-negative, hormone receptor-
positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. While 
the RS was initially known to be associated with distant metastasis [7], subsequent studies 
showed that it also predicts locoregional recurrence (LRR) [8-10]. However, only a few 
studies have investigated whether the RS is associated with regional recurrence alone and 
whether it can be used for selecting a subgroup of patients who will benefit from regional RT.
Therefore, the current study aimed to evaluate the impact of the Oncotype DX RS on the 
patterns of LRR in patients who underwent BCS and postoperative RT for node-negative, 
hormone receptor-positive/HER2-negative breast cancer.
The medical records of 401 patients who underwent RT after BCS for node-negative, 
hormonal receptor-positive/HER2-negative breast cancer between January 2010 and 
December 2015 and whose Oncotype DX RS was available were retrospectively reviewed. 
After excluding 62 patients whose RT field data were unavailable, a total of 339 patient from 
4 institutions were included in this study. The institutional review board approved this study 
(H-1909-024-1060) and waived the requirement for informed consent.
All the patients underwent BCS and sentinel lymph node (LN) biopsy, or BCS and axillary 
LN dissection. None of them received neoadjuvant systemic therapy. After Oncotype 
DX testing, systemic therapy was performed at the treating physician's discretion. If a 
chemotherapy regimen—apart from the cyclophosphamide, methotrexate, and 5-fluorouracil 
regimen (which was administered concomitantly with RT)—was offered, postoperative RT 
was administered after the completion of chemotherapy. All the patients received whole-
breast RT, and only 2 patients received regional RT to the supraclavicular fossa. A total of 
302 patients received conventional fractionated RT (50–50.4 Gy in 25–28 fractions) and 
37 received hypofractionated RT (39–43.2 Gy in 13–16 fractions). Tumor bed boost was 
performed for all patients, except 1.
We evaluated local, regional, and distant recurrences. Recurrences in the ipsilateral breast 
were defined as local recurrences, and those in the ipsilateral axillary, supraclavicular, and/
or internal mammary LNs as regional recurrences. Distant recurrences indicated tumor 
recurrences outside the regions identified as locoregional sites. The SPSS software (release 
18.0.1. SPSS Inc., Chicago, USA) was used for statistical analysis.
The median age of all the patients was 47 years (range, 29–77 years). A total of 164 patients had 
right breast cancer and 175 had left breast cancer. Regarding the tumor location, 119 patients had 
inner tumors, 170 had outer tumors, and 49 had central tumors. One patient had multicentric 
tumors. Two hundred ninety-nine patients had invasive ductal carcinomas (88.2%). The 
pathologic tumor size ranged from 0.4 cm to 5.5 cm (median, 1.6 cm). Totally, 233 patients 
(68.7%) had T1 tumors while 105 (31.0%) had T2 tumors. Only 1 patient had a T3 tumor. The 
histologic grade was 3 in 57 patients (16.8%), and lymphovascular invasion was observed in 74 
patients (21.8%). The patient and tumor characteristics are summarized in Table 1.
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The Oncotype DX RS ranged from 0 to 71 (median, 17). The RS was < 11 in 55 patients 
(16.2%), 11–25 in 241 patients (71.1%), and >25 in 43 patients (12.7%). Of the 296 patients, 24 
patients (8.1%) with a RS ≤ 25 received chemotherapy. Among the 43 patients with a RS > 25, 
5 patients (11.6%) did not receive chemotherapy.
A total of 62 patients received systemic chemotherapy. The chemotherapeutic regimens 
were doxorubicin and cyclophosphamide in 28 patients; 5-fluorouracil, doxorubicin and 
cyclophosphamide in 23; docetaxel and cyclophosphamide in 6; cyclophosphamide, 
methotrexate, and 5-fluorouracil in 4; doxorubicin and cyclophosphamide followed by 
paclitaxel in 1. All the patients underwent hormonal therapy, except for 4 patients who wanted 
to get pregnant in future. A total of 265 patients received tamoxifen, 62 received an aromatase 
inhibitor, and 8 received tamoxifen initially and switched to an aromatase inhibitor.
The median duration of follow-up was 62 months (range, 17–109 months). Local recurrence 
was observed in 1 patient, regional recurrence in 3 patients, and distant metastasis in 7 
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Table 1. Patient, tumor, and treatment characteristics (n = 339)
Variables No. of patients (%)
Age (yr)
Median (range) 47 (29–77)
Pathology
Invasive ductal carcinoma 299 (88.2)


















Positive (invasive carcinoma) 15 (4.4)
Positive (intraductal carcinoma) 3 (0.9)
Recurrence score
< 11 55 (16.2)
11–25 241 (71.1)








None (breast RT only) 337 (99.4)
Supraclavicular node 2 (0.6)
Internal mammary node 0 (0.0)
RT = radiotherapy.
patients. All the cases of LRR were observed among those patients with a RS >25, resulting in 
a 5-year LRR rate of 7.3% in this subgroup. The regional recurrence sites were the axillary LNs 
in 2 patients and the supraclavicular LN in 1 patient, none of whom had received regional RT 
initially. The detailed summary of recurrences is shown in Table 2.
The current study analyzed the outcomes of BCS plus RT for node-negative, hormonal 
receptor-positive/HER2-negative breast cancer according to the Oncotype DX RS. LRR was 
observed in only 4 patients, all of whom had a RS > 25. In addition, patients with regional 
recurrences did not receive regional RT initially.
The Oncotype DX RS is well known to be associated with distant metastasis [7], and 
the correlation with LRR has been reported in several studies [8,9]. For example, in the 
combined analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 
and B-20 trials, the 10-year LRR rates of the low (< 18), intermediate (18–30), and high RS 
(> 30) groups were 4.3%, 7.2%, and 15.8%, respectively (p < 0.0001), in patients receiving 
tamoxifen [8]. In those patients receiving chemotherapy and tamoxifen, the corresponding 
values were 1.6%, 2.7%, and 7.8%, respectively (p = 0.028). Moreover, Turashvili et al. [9] 
from the Memorial Sloan Kettering Cancer Center observed that the 4-year LRR rates of 
the low, intermediate, and high RS groups were 0.84%, 2.72%, and 2.80%, respectively (p < 
0.01). Although these studies suggest that the LRR rate was significantly separated by using 
the RS, the differences in the local and systemic treatments as well as the follow-up duration 
should be considered in the interpretation. In addition, the risk factors other than RS should 
be considered. Moreover, age, type of surgery [8], T stage, and lymphovascular invasion [9] 
were additional prognostic factors for LRR in the multivariate analyses performed in the 
aforementioned studies. In the current study, we adopted a cutoff value of 25 for the RS from 
the TAILORx trial [11]. All the patients underwent BCS and RT, and 88% of patients with a RS 
> 25 received chemotherapy. Although risk factor analysis could not be performed owing to 
the small number of events, all the 4 cases of LRR were observed in patients with a high RS, 
consistent with the observations in previous studies.
Considering the correlation between the RS and LRR, many studies are underway to guide 
the optimal indications of RT. Most of these studies are focusing on the necessity of post-
mastectomy RT for patients with pT1-2N1 breast cancer [12,13] or the omission of whole-
breast RT after BCS for patients with a low RS [14,15]. Meanwhile, only a few studies are 
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Table 2. Summary of recurrences
















Local* 37 1.5 III No Negative 49 AC #4 Tamoxifen 37 mon
Regional (axillary LN) 61 1.3 II No Negative 30 FAC #6 AI 20 mon
Regional (supraclavicular LN)† 56 1.6 II Yes Negative 28 AC #4 Tamoxifen 49 mon
Regional (axillary LN)* 37 1.5 III No Negative 49 AC #4 Tamoxifen 51 mon
Distant (lung) 40 2 III Yes Negative 29 FAC #6 Tamoxifen 19 mon
Distant (mediastinal LN & bone) 49 2 III No Negative 24 No Tamoxifen 21 mon
Distant (liver) 61 2.4 II No Negative 12 No Tamoxifen 7 mon
Distant (bone, lung, liver)† 56 1.6 II Yes Negative 28 AC #4 Tamoxifen 49 mon
Distant (bone) 32 3.1 III No Negative 22 AC #4 Tamoxifen 70 mon
Distant (lung)* 37 1.5 III No Negative 49 AC #4 Tamoxifen 51 mon
Distant (bone) 49 2.5 II Yes Negative 15 No Tamoxifen 58 mon
LN = lymph node; AC = doxorubicin and cyclophosphamide; FAC = 5-fluorouracil, doxorubicin and cyclophosphamide; AI = aromatase inhibitor.
*This patient experienced local recurrence first, and subsequently regional and distant recurrences 14 months later; †This patient experienced simultaneous 
regional and distant recurrences.
investigating whether the RS is associated with regional recurrence alone and if it can be used 
to select the subgroup of patients who will benefit from regional RT. Mamounas et al. [16] 
analyzed the correlation between the RS and LRR in a subgroup of the NSABP B-28 trial, in 
which all patients were treated with chemotherapy and hormonal therapy. Among patients 
with 1–3 positive LNs who underwent BCS + RT, the 10-year regional recurrence rates of the 
low, intermediate, and high RS groups were 0%, 0%, and 3.5%, respectively. Even in patients 
with ≥ 4 positive LNs, the corresponding values were as low as 0%, 2%, and 0%, respectively. 
Regional recurrences were also rare in the aforementioned studies involving node-negative 
patients. In the NSABP B-14 and B-20 trials, axillary LN recurrence was observed in 1 patient, 
supraclavicular LN recurrence in 3 patients, and local and regional recurrence (location 
not specified) in 1 patient in the BCS + RT + tamoxifen group (n = 390) [8]. Data from the 
Memorial Sloan Kettering Cancer Center showed that axillary LN recurrence was observed in 
7 patients, supraclavicular LN recurrence in 2 patients, and internal mammary LN recurrence 
in 1 patient, among a total of 2,326 patients [9]. In the current study, regional recurrence was 
observed in only 3 patients among 339 patients, but these patients did not receive regional RT 
initially. As the 5-year LRR rate was 7.3% in patients with a RS > 25 and 88% of these patients 
received standard chemotherapy, these findings suggest that more comprehensive regional 
RT might be considered for these patients.
In the current study, the surgical resection margin was involved in 18 patients (15 with 
invasive carcinoma and 3 with intraductal carcinoma), but all of them were free of LRR. The 
surgical resection margin is among the most important prognostic factors for LRR. However, 
8 of these patients had involvement of the superficial or deep margin, which is known to 
have a lesser impact on LRR [17]. In addition, 10 of these patients received a higher dose 
of tumor bed boost (12.5–15 Gy in 3–6 fractions), which might contribute to the increased 
local control, although such a dose-response relationship was not observed in a previous 
randomized controlled trial [18].
The present study includes the typical shortcomings associated with a retrospective study 
design, such as selection bias. In addition, as LRR was observed in only 4 patients, risk 
factors such as surgical resection margin could not be analyzed further. Moreover, the follow-
up period was relatively short considering the indolent course of node-negative, hormone 
receptor-positive breast cancer. Hence, further studies with a larger population and long-
term follow-up are warranted to validate the findings of the current study.
In conclusion, excellent locoregional control was achieved in patients with node-negative, 
hormone receptor-positive/HER2-negative breast cancer who underwent BCS plus RT—
including risk-adapted systemic therapy—according to the Oncotype DX RS. As regional 
recurrence was observed only in patients with a RS > 25 who were treated with only breast RT, 
regional RT might be considered for those patients with a high RS.
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